Cargando…

Healthcare professionals & adverse events of ChAdOx1 nCoV-19 coronavirus vaccine

Detalles Bibliográficos
Autores principales:	Mungmunpuntipantip, Rujittika, Wiwanitkit, Viroj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807199/ https://www.ncbi.nlm.nih.gov/pubmed/36124501 http://dx.doi.org/10.4103/ijmr.ijmr_373_22

Ejemplares similares

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Comment on “Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination”
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Lodge, Archie
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply
por: Voysey, Merryn, et al.
Publicado: (2020)

Fatal myositis, rhabdomyolysis and compartment syndrome after ChAdOx1 nCoV-19 vaccination
por: Huang, Szu-Ting, et al.
Publicado: (2022)

Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey
por: Kaur, Sukhpal, et al.
Publicado: (2022)

Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients
por: Vaishya, Raju, et al.
Publicado: (2021)

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
por: Tenbusch, Matthias, et al.
Publicado: (2021)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
por: Hillson, Kushalinii, et al.
Publicado: (2021)

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
por: Soboleva, Karina, et al.
Publicado: (2022)

Effectiveness of ChAdOx1 nCOV-19 Vaccine: Experience of a tertiary care institute
por: Koshy, George
Publicado: (2022)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant
por: Sheikh, Aziz, et al.
Publicado: (2021)

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India
por: Chakrabarti, Sasanka, et al.
Publicado: (2022)

Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers
por: Hyun, JongHoon, et al.
Publicado: (2022)

Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal
por: Rayamajhi, Sushil, et al.
Publicado: (2022)

Delayed large local reaction to the adenovirus-vectored (ChAdOx1) vaccine
por: Grobusch, Martin P., et al.
Publicado: (2021)

Central nervous system adverse events after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2022)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination
por: Öcal, Osman, et al.
Publicado: (2021)

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination
por: Spataro, Rossella, et al.
Publicado: (2022)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Schultz, Nina H., et al.
Publicado: (2021)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
por: Berlot, Giorgio, et al.
Publicado: (2022)

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19()
por: Morales Varas, G., et al.
Publicado: (2022)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
por: Garibashvili, Tamara, et al.
Publicado: (2022)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
por: Krutzke, Lea, et al.
Publicado: (2022)

Split-dosing of coronavirus disease 2019 vaccines
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study
por: Velhal, Gajanan D., et al.
Publicado: (2022)

Aseptic Meningitis and mRNA Coronavirus Disease 2019 Vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea
por: Jeon, Minji, et al.
Publicado: (2021)

Uncertainty in using chest computed tomography in early coronavirus disease (COVID-19)
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2020)

No Correlation between Anti-PF4 and Anti–SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination
por: Uzun, Günalp, et al.
Publicado: (2021)

Acute ST-Segment Elevation Myocardial Infarction After ChAdOx1 nCoV-19 Vaccination in a 33-Year-Old Man
por: Hsu, Ming Hung, et al.
Publicado: (2022)

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India – Authors' reply
por: Thiruvengadam, Ramachandran, et al.
Publicado: (2022)

Antibody response to coronavirus disease 2019 vaccines after allergic reaction to first dose: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021
por: Konu, Yao Rodion, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q2skcsaac51li0juhlql6mhodv